Previous 10 | Next 10 |
2023-07-26 05:13:00 ET If you've only recently learned about Invitae (NYSE: NVTA) , you can consider yourself lucky. A few years ago, the diagnostics business wowed Wall Street with plans to bring genetic testing to the masses. Investors convinced it would become a leading provider ...
2023-07-16 01:18:55 ET Summary Invitae, a genetic testing services provider, reported Q1 2023 revenue of $117.4 million, down from Q1 2022's $123.7 million due to exited businesses and geographies. However, after accounting for these exits, revenue grew 10% YoY. The company has si...
2023-06-26 05:30:00 ET Sometimes, a company hits a stumbling block -- or several of them. The stock plummets, and investors lose faith. But, in some cases, these down-on-their luck companies are able to turn things around. And if you spot signs of a bright future early enough, you can get i...
2023-06-07 17:40:25 ET Invitae Corporation (NVTA) Annual William Blair Growth Stock Conference Call June 7, 2023 13:40 PM ET Company Participants Ken Knight - President and Chief Executive Officer Hoki Luk - Investor Relations Conference Call Participants ...
2023-06-05 14:00:00 ET One of the exciting parts of investing is identifying companies that will offer us the next big thing. This could be a game-changing drug or an exciting technology that may transform healthcare. And two companies Wall Street is bullish on have that potential. In...
Invitae to Present at the William Blair 43rd Annual Growth Stock Conference PR Newswire SAN FRANCISCO , May 31, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight , president and chief execut...
New Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology PR Newswire – Study findings confirm the importance of improving education among clinicians and streamlining processes to i...
2023-05-26 02:03:20 ET Invitae ( NYSE: NVTA ) notifies that Chief Financial Officer Yafei (Roxi) Wen is resigning to pursue other opportunities, effective June 30, 2023. A search for successor is underway. Ms. Wen will continue in her role through the end of the ...
Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO PR Newswire SAN FRANCISCO , May 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Chief Financia...
2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...